ClinicalTrials.gg
RecruitingNCT07144189ASAI-POLUpdated Dec 2, 2025

AI Assessment of Low-Gradient Aortic Stenosis Severity Based on Echocardiography

An observational study in Low-gradient Aortic Stenosis and Aortic Stenosis, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by National Institute of Cardiology, Warsaw, Poland · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Aortic Valve Stenosis with a site in Poland — 10 open to participants now, 11 under way, 1 of them phase 3. Aortic Valve Stenosis · Poland.

Planned enrollment
7th of 14
300 · median 250
Started
2025
with 3 others
Observational
14 of 30
5 open now
Primary completion
2026-08
later than 7 of 10 live
Registered
29th of 30
by date

Among the 30 studies in Aortic Valve Stenosis with a site in Poland, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 29th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

10 of the 30 studies in Aortic Valve Stenosis with a site in Poland are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Aortic Valve Stenosis with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of an artificial intelligence (AI) model developed by the investigators for identifying severe low-gradient aortic valve stenosis. Accurate assessment of stenosis severity is crucial for proper qualification for surgical treatment. It is expected that the use of AI will improve diagnostic accuracy and thereby support better clinical outcomes.

Patients with suspected significant low-gradient aortic stenosis will be enrolled. The study is observational and involves no additional risk for participants. Standard imaging studies performed for clinical indications will be additionally analyzed by the AI model, which will classify aortic stenosis as severe or moderate. The model's results will not influence the clinical management of participants but will be compared with physicians' assessments to validate its diagnostic performance.

The study will be conducted in 2025-2026. The findings will provide insights into the usefulness of AI in the diagnosis of severe aortic stenosis and may contribute to the development of advanced clinical decision-support tools.

Read the detailed description

This study is a prospective multicenter observational validation of an artificial intelligence (AI) model for differentiating severe low-gradient from moderate aortic stenosis using transthoracic echocardiography images. The model, developed and published by the investigators, demonstrated promising diagnostic performance in retrospective data. In the present trial, approximately 300 participants with suspected significant low-gradient aortic stenosis will be enrolled during 2025-2026. Standard imaging studies performed for clinical indications will be analyzed by the AI model, which will classify aortic stenosis as severe or moderate. The AI-derived results will not influence clinical decision-making but will be compared with physicians assessments to evaluate diagnostic accuracy and reproducibility in real-world practice.

03

Conditions studied

  • Low-gradient Aortic Stenosis
  • Aortic Stenosis

Keywords

  • low-gradient aortic stenosis
  • Echocardiography
  • Artificial intelligence
  • Cardiac imaging
  • Machine learning
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include adult patients (≥18 years) diagnosed in the Echocardiography Laboratory of the National Institute of Cardiology in Warsaw, Department of Valvular Heart Disease. Eligible participants will be those referred for echocardiographic evaluation due to clinical suspicion of significant low-gradient aortic stenosis. Standard-of-care imaging performed for clinical indications will be analyzed. Approximately 300 patients are expected to be enrolled between 2025 and 2026. Patients with previous aortic valve intervention (surgical or transcatheter) or other exclusion criteria will not be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Clinical suspicion of significant low-gradient aortic stenosis
  • Echocardiographic examination performed for clinical indications
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Previous aortic valve intervention (surgical or transcatheter)
  • Inadequate image quality precluding echocardiographic analysis
  • Concomitant severe valvular disease (severe mitral stenosis or mitral/aortic regurgitation) that could confound assessment
  • Patients unwilling or unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with suspected significant low-gradient aortic stenosis.

    Approximately 300 patients with suspected significant low-gradient aortic stenosis undergoing standard echocardiographic evaluation between 2025 and 2026. Echocardiographic images will be secondarily analyzed by the AI model to classify stenosis as severe or moderate. The AI results will be compared with physicians assessments. No intervention or modification of clinical care is involved.

    Diagnostic Test: AI diagnostic test for severe low-gradient aortic stenosis

Interventions

  • Diagnostic testAI diagnostic test for severe low-gradient aortic stenosis

    All participants will undergo standard transthoracic echocardiography performed for clinical indications. Echocardiographic images will be analyzed both by experienced physicians and by the investigational AI model. Additional diagnostic tests (such as cardiac CT, low-dose dobutamine stress echocardiography or transesophageal echocardiography) may be performed if clinically indicated, according to current guideline recommendations. The AI-derived results will not influence clinical decision-making.

06

What researchers measure

Primary outcomes

  1. Area Under the Receiver Operating Characteristic Curve (AUC) describing the sensitivity-specificity relationship of the AI model.

    AUC will be calculated to assess the ability of the AI model to differentiate between severe low-gradient and moderate aortic stenosis. The analysis will use physician assessment and guideline-based diagnostic criteria as the reference standard. AUC will be reported with 95% confidence intervals.

    Time frame: At the time of the nearest Heart Team meeting following the echocardiographic examination (typically within 1 week).

Secondary outcomes

  1. Diagnostic performance of the AI model in clinically relevant subgroups.

    Diagnostic performance of the AI model (AUC, sensitivity, specificity) in clinically relevant subgroups, such as patients with atrial fibrillation or subtypes of low-gradient aortic stenosis (classic, paradoxical, normal flow).

    Time frame: At the nearest Heart Team meeting following the echocardiographic examination (typically within 1 week).

07

Study locations

1 of 1 sites recruiting
  • Department of Valvular Heart Disease, National Institute of Cardiology, Warsaw, Poland
    Warsaw, Masovian Voivodeship, Poland
    Recruiting
08

References and documents

Publications

  • Wrzosek M, Buchwald M, Czernik P, Kupinski S, Zatorska K, Jasinska A, Zakrzewski D, Pukacki J, Mazurek C, Pekal R, Hryniewiecki T. Diagnosing Severe Low-Gradient vs Moderate Aortic Stenosis with Artificial Intelligence Based on Echocardiography Images. J Imaging Inform Med. 2026 Feb;39(1):926-932. doi: 10.1007/s10278-025-01497-4. Epub 2025 Apr 21. PubMed 40259202 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 12 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 12 months is below that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Aug 27, 2025
StartActual
Aug 20, 2025
Primary completionEst.
Aug 20, 2026
CompletionEst.
Aug 20, 2026
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07144189
Lead sponsor
National Institute of Cardiology, Warsaw, Poland
Collaborators
The Institute of Bioorganic Chemistry, Polish Academy of Sciences
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Aug 20, 2025
Primary completion
Aug 20, 2026 (estimated)
Completion
Aug 20, 2026 (estimated)
Last update
Dec 2, 2025

Study contacts

Michał Wrzosek, MD
Contact
mwrzosek@ikard.pl
+48 22 3434189
Tomasz Hryniewiecki, Professor of Medicine
Contact
thryniewiecki@ikard.pl
+48 223434180
Tomasz Hryniewiecki, Professor of Medicine
study chair · Department of Valvular Heart Disease, National Institute of Cardiology, Warsaw, Poland
Michał Wrzosek, MD
principal investigator · Department of Valvular Heart Disease, National Institute of Cardiology, Warsaw, Poland
Karina Zatorska, MD, PhD
study director · Department of Valvular Heart Disease, National Institute of Cardiology, Warsaw, Poland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion